WO2004003167A3 - Gucy1b2 genetic markers for ldl cholesterol response to statin therapy - Google Patents
Gucy1b2 genetic markers for ldl cholesterol response to statin therapy Download PDFInfo
- Publication number
- WO2004003167A3 WO2004003167A3 PCT/US2003/020606 US0320606W WO2004003167A3 WO 2004003167 A3 WO2004003167 A3 WO 2004003167A3 US 0320606 W US0320606 W US 0320606W WO 2004003167 A3 WO2004003167 A3 WO 2004003167A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gucy1b2
- genetic markers
- ldl cholesterol
- methods
- response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003280285A AU2003280285A1 (en) | 2002-06-28 | 2003-06-30 | Gucy1b2 genetic markers for ldl cholesterol response to statin therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39281802P | 2002-06-28 | 2002-06-28 | |
US60/392,818 | 2002-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004003167A2 WO2004003167A2 (en) | 2004-01-08 |
WO2004003167A3 true WO2004003167A3 (en) | 2005-02-10 |
Family
ID=30000940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/020606 WO2004003167A2 (en) | 2002-06-28 | 2003-06-30 | Gucy1b2 genetic markers for ldl cholesterol response to statin therapy |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003280285A1 (en) |
WO (1) | WO2004003167A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1784504A2 (en) * | 2004-07-21 | 2007-05-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Oatp-c gene c463a polymorphism underlies variable response of statin therapy |
-
2003
- 2003-06-30 AU AU2003280285A patent/AU2003280285A1/en not_active Abandoned
- 2003-06-30 WO PCT/US2003/020606 patent/WO2004003167A2/en not_active Application Discontinuation
Non-Patent Citations (3)
Title |
---|
AHREN, H.: "Biochemical, reagent kits offer scientists good return on investment", THE SCIENTIST, vol. 19, 24 July 1995 (1995-07-24), pages 20 - 24, XP002921157 * |
BEHRENDS ET AL.: "The beta2 subunit of soluble guanylyl cyclase contains a human-specific frameshift and is expressed in gastric carcinoma", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 271, 2000, pages 64 - 69, XP001197340 * |
DATABASE GENBANK, ON NCBI [online] XP002904285, Database accession no. (AF038499) * |
Also Published As
Publication number | Publication date |
---|---|
WO2004003167A2 (en) | 2004-01-08 |
AU2003280285A1 (en) | 2004-01-19 |
AU2003280285A8 (en) | 2004-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006063704A3 (en) | Single nucleotide polymorphism (snp) associated to type ii diabetes | |
AU2003257110A1 (en) | Polymorphisms for predicting disease and treatment outcome | |
WO2004011611A3 (en) | Taci antibodies and uses thereof | |
WO2004113277A3 (en) | Methods and compositions for treating amyloid-related diseases | |
EP1765388B8 (en) | Combination therapy for preventing or treating alzheimer's disease, and kit therefor | |
GB0213612D0 (en) | Organic compounds | |
WO2005027966A3 (en) | Antibodies with altered effector functions | |
WO2004103960A3 (en) | Compounds and uses thereof | |
WO2004014312A3 (en) | Small-mer compositions and methods of use | |
AU2003221745A1 (en) | rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES | |
AU2003223367A1 (en) | Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles | |
WO2005072151A3 (en) | Apoe genetic markers associated with age of onset of alzheimer's disease | |
AU2003300368A1 (en) | Methods and compositions for the diagnosis, prognosis, and treatment of cancer | |
WO2004098377A3 (en) | Methods and compositions for diagnosis and therapy of parkin-associated disorders | |
WO2002058733A3 (en) | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
AU2002338852A1 (en) | Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease | |
WO2006063703A3 (en) | Single nucleotide polymorphism (snp) associated to type ii diabetes | |
WO2003087315A3 (en) | Pre-and post therapy gene expression profiling to identify drug targets | |
WO2004033710A3 (en) | Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol | |
WO2005059105A3 (en) | Cdk5 genetic markers associated with galantamine response | |
WO2005072152A3 (en) | Apoc1 genetic markers associated with age of onset of alzheimer's disease | |
WO2003087325A3 (en) | Methods and compositions for preventing and treating microbial infections | |
WO2005019269A3 (en) | Techniques and compositions for the diagnosis and treatment of cancer (muc1) | |
WO2004003167A3 (en) | Gucy1b2 genetic markers for ldl cholesterol response to statin therapy | |
WO2003076610A3 (en) | Variants of human kallikrein-2 and kallikrein-3 and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |